{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-303995","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2023-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.339894+00:00","generated_at":"2026-06-07T07:10:54.818088+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MannKind restructures Amphastar supply deal: lowers annual commitments, adds capacity fees","bullets":["Prior total purchase commitments of €58.7M for 2024-27 replaced; new commitments for 2024 = €2.9M, 2025 = €1.5M.","Capacity fee introduced: €2M/year in Year 1 of new supply, decreasing to €500k/year in Years 6-9.","Term extended to later of Dec 31, 2035 or completion of purchase commitments.","Amendment accommodates change in source of inclusion bodies (insulin intermediate) to Amphastar-manufactured."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-303995","json":"https://secwatch.observer/filing/0001193125-23-303995.json","markdown":"https://secwatch.observer/filing/0001193125-23-303995.md","text":"https://secwatch.observer/filing/0001193125-23-303995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000119312523303995/0001193125-23-303995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000119312523303995/d57247d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:10:54.818088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ccd277d06115f49554347a928e1bba38df8bdc1b","claim":"MANNKIND CORP amended Seventh Amendment to Supply Agreement with Amphastar Pharmaceuticals, Inc. valued at €2.9 million annual purchase commitment for 2024; amended purchase commitments through 2035 (effective 2023-12-22).","evidence_excerpt":"On December 22, 2023, MannKind Corporation (the “Company”) entered into a Seventh Amendment to Supply Agreement (the “Seventh Amendment”) with Amphastar Pharmaceuticals, Inc. pursuant to which the parties amended the Supply Agreement, dated July 31, 2014, as amended (the “Supply Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312523303995/0001193125-23-303995-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Amphastar Pharmaceuticals, Inc."},{"label":"Value","value":"€2.9 million annual purchase commitment for 2024; amended purchase commitments through 2035"},{"label":"Effective","value":"2023-12-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}